The FDA just lost its commissioner the way families lose trust in institutions: suddenly, after months of quiet pressure, and with one text message that said almost nothing.
Quick Take
- Dr. Marty Makary resigned as FDA commissioner on May 12, 2026, after intensifying internal tensions and outside political pressure.
- Two policy flashpoints dominated the conflict: approval of flavored e-cigarettes and the handling of the abortion drug mifepristone.
- President Trump publicly described Makary as a “great guy” who was “having some difficulty,” without detailing the dispute.
- Kyle Diamantas stepped in as acting commissioner, leaving the agency in an interim posture during high-stakes decisions.
The resignation that turned an independent regulator into a political weather vane
Dr. Marty Makary resigned Tuesday, May 12, 2026, ending a tenure defined less by lab coats and more by leverage.
The timeline matters because it shows momentum: an FDA decision on May 6 approving flavored e-cigarettes from Glas Inc. reportedly came after White House pressure, and Makary then vanished from a May 12 Oval Office maternal health event where his presence would have signaled stability. By afternoon, a resignation text hit the President’s phone.
Makary’s message was short—“the honor of a lifetime”—and the brevity carried its own meaning. Washington resignations rarely happen when everything is fine; they happen when the next step is termination, humiliation, or a forced retreat.
Trump’s public comments framed Makary as personally likable yet professionally stuck, saying he was “having some difficulty.” That vague phrase invites a real question for anyone who cares about accountable government: difficulty with science, or difficulty with politics?
Flavored vapes: the policy fight that reveals who actually holds the pen
Flavored e-cigarettes sit at the intersection of adult choice, harm-reduction claims, and a genuine concern about youth uptake. That makes them perfect political kindling.
Reports described Makary as resisting approvals for fruit-flavored products until pressure arrived from above, after which the FDA approved products tied to Glas Inc. A regulator who can be leaned on for a headline-grabbing decision becomes less of a referee and more of a scoreboard operator.
US FDA Commissioner Marty Makary resigned, President Trump said, after weeks of clashing with top White House and health advisers and drawing scrutiny for a series of controversial decisions, according to several people familiar with internal dynamics https://t.co/NumUuKkfFJ pic.twitter.com/HhmdfGW1J9
— Reuters Health (@Reuters_Health) May 12, 2026
Less red tape is preferred, but common sense draws a hard line between “streamline the process” and “pre-decide the outcome.” Industry deserves predictable rules, not a backchannel. Parents deserve credible safeguards, not whiplash.
When the White House appears to push an agency toward a specific approval, the real casualty is trust: the next time the FDA says a product is safe—or risky—half the country will assume the conclusion was negotiated, not reached.
Mifepristone: a slow-walk allegation that became a firing slogan
The mifepristone dispute worked differently. In June 2025, HHS Secretary Robert F. Kennedy Jr. asked Makary to review the drug with an emphasis on “real-world outcomes and evidence.”
By December 2025, reports said Makary “slow-walked” that study, and Susan B. Anthony Pro-Life America and other groups demanded he be removed, using plain language: “Makary must go.” That kind of public pressure campaign rarely ends with a quiet handshake.
Many Americans tend to view abortion policy through the lens of protecting unborn life and demanding institutional honesty. Those values collide with the FDA’s mission when politics replaces process. If Makary delayed the review, critics will ask why; if he hurried it, opponents would accuse him of rigging.
The cleanest answer is transparency and timelines that look like governance, not tactics. The available reporting suggests neither side believed they were getting that.
Management turmoil inside the FDA: the unglamorous detail that often decides careers
Policy disputes make the headlines, but internal management complaints often supply the exit ramp. Senior officials reportedly cited concerns about Makary’s micromanagement and transparency, the kinds of issues that poison an agency where career experts expect stable chains of command.
Leaders can be brilliant and still fail at operating a bureaucracy. In a high-pressure White House, that weakness becomes a tool: once staff confidence slips, outside actors can argue the commissioner is “unstable” without debating the substance.
Makary’s background also mattered. He rose to prominence during COVID-19 as a contrarian voice on lockdowns and public health measures, which earned him fans who wanted a less paternalistic medical establishment. That brand plays well politically, but the FDA is a paperwork-and-proof institution.
The commissioner must persuade scientists, lawyers, and inspectors, not just cable news audiences. When persuasion fails, politics fills the vacuum, and resignations start to look like policy outcomes.
What Kyle Diamantas inherits: an agency trapped between public health and presidential priorities
Trump tapped Kyle Diamantas, the deputy commissioner for food, as acting commissioner. Acting leadership rarely signals calm; it signals a holding pattern while the real fight continues offstage. The near-term risk is delay—major decisions slow down when everyone waits for the permanent boss.
The longer-term risk is acceleration in the wrong direction—an acting commissioner may feel pressure to prove loyalty by moving quickly on politically sensitive files like vaping and abortion drugs.
Makary’s resignation also sets a precedent: commissioners who resist either industry demands or ideological demands may discover they can’t resist both at once. Americans should want an FDA that is lean, predictable, and accountable, not an agency that changes its posture with every pressure wave.
The solution isn’t to pretend politics can be removed from regulation; it’s to force politics into daylight—clear standards, published rationales, and leadership that can’t be pushed around by the loudest stakeholder in the room.
Sources:
Marty Makary FDA commissioner resigns Trump
